CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.
Fiche publication
Date publication
mai 2015
Journal
Oncoimmunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF
Lien Pubmed
Résumé
We report that CD39-expressing-melanoma cells inhibited both T-cell proliferation and the generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore antitumor immunity.
Mots clés
CD39, immune checkpoints, A2A receptor, adenosine, PD1
Référence
Oncoimmunology. 2015 05;4(5):e1003015